4569 Stock Overview
Through its subsidiaries, researches and develops, manufactures, and sells ethical and generic drugs in Japan and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 5/6 |
| Dividends | 1/6 |
KYORIN Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥1,683.00 |
| 52 Week High | JP¥1,880.00 |
| 52 Week Low | JP¥1,646.00 |
| Beta | -0.068 |
| 11 Month Change | 1.75% |
| 3 Month Change | -6.97% |
| 1 Year Change | -2.26% |
| 33 Year Change | -4.32% |
| 5 Year Change | -9.90% |
| Change since IPO | 13.79% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4569 | JP Pharmaceuticals | JP Market | |
|---|---|---|---|
| 7D | -1.1% | 3.6% | 2.4% |
| 1Y | -2.3% | 16.4% | 24.6% |
Return vs Industry: 4569 underperformed the JP Pharmaceuticals industry which returned 16.4% over the past year.
Return vs Market: 4569 underperformed the JP Market which returned 24.6% over the past year.
Price Volatility
| 4569 volatility | |
|---|---|
| 4569 Average Weekly Movement | 2.1% |
| Pharmaceuticals Industry Average Movement | 3.7% |
| Market Average Movement | 3.8% |
| 10% most volatile stocks in JP Market | 7.3% |
| 10% least volatile stocks in JP Market | 1.9% |
Stable Share Price: 4569 has not had significant price volatility in the past 3 months.
Volatility Over Time: 4569's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1923 | 2,042 | Yutaka Ogihara | www.kyorin-pharm.co.jp |
KYORIN Pharmaceutical Co., Ltd., through its subsidiaries, researches and develops, manufactures, and sells ethical and generic drugs in Japan and internationally. The company offers Flutiform, a drug for the treatment of asthma; Lyfuna for cough treatment; Desalex, an antiallergic agent; Beova, Uritos, and Imidafenacin KYORIN therapeutic agents for overactive bladder; Lasvic, a quinolone synthetic antibacterial agent; Pentasa, a remedy for ulcerative colitis/Crohn's disease; Nasonex and Mometasone KYORIN, which are used as allergic rhinitis therapeutic agents; and Kipres, a leukotriene receptor antagonist anti-bronchial asthma and allergic rhinitis drug. It also provides Mucodyne, a mucoregulating drug; Montelukast KM, a drug for the treatment of bronchial asthma and allergic rhinitis; GeneSoC, a real-time PCR system; Rubysta, a disinfectant cleaner; Milton, a disinfectant; over-the-counter drugs; prescription medicines and quasi-drugs, diagnostics, and industrial chemicals; and reagents, intermediates, and other products.
KYORIN Pharmaceutical Co., Ltd. Fundamentals Summary
| 4569 fundamental statistics | |
|---|---|
| Market cap | JP¥96.69b |
| Earnings (TTM) | JP¥5.32b |
| Revenue (TTM) | JP¥119.53b |
18.2x
P/E Ratio0.8x
P/S RatioIs 4569 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4569 income statement (TTM) | |
|---|---|
| Revenue | JP¥119.53b |
| Cost of Revenue | JP¥68.12b |
| Gross Profit | JP¥51.41b |
| Other Expenses | JP¥46.09b |
| Earnings | JP¥5.32b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Jul 31, 2024
| Earnings per share (EPS) | 92.64 |
| Gross Margin | 43.01% |
| Net Profit Margin | 4.45% |
| Debt/Equity Ratio | 15.9% |
How did 4569 perform over the long term?
See historical performance and comparison